Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort
- PMID: 17239691
- DOI: 10.1016/j.ahj.2006.10.030
Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort
Abstract
Background: The aim of our prospective multicenter Clopidogrel Registry was to evaluate the efficacy and safety of a 300-mg loading dose of clopidogrel at the time of ad hoc stenting in patients with suspected coronary artery disease who were not pretreated with clopidogrel for any reason, and to compare the 30-day clinical event rates with the outcome of patients pretreated with a loading dose of clopidogrel 6 to 24 hours before stenting.
Methods: Between March 2002 and February 2004, 4160 consecutively included patients received a 300-mg loading dose of clopidogrel immediately after (group 1, n = 2679) or 6 to 24 hours before stenting (group 2, n = 1481).
Results: The primary end point (triple composite end point of acute myocardial infarction, all-cause death, and urgent repeat target vessel revascularization) at 30 days occurred in 4.74% versus 2.77% in groups 1 and 2, respectively (P = .002). The secondary end point events, the stent thrombosis, occurred significantly more frequently in group 1, with a trend toward increase in incidence of death, target vessel revascularization, or need for glycoprotein IIb/IIIa antagonists during percutaneous coronary intervention. Pretreatment with clopidogrel was associated with more major bleeding (secondary safety end point) (0.41% vs 1.35% in groups 1 and 2, respectively; P = .001).
Conclusions: The results of our multicenter prospective Clopidogrel Registry demonstrate lower efficacy of a 300-mg loading dose of clopidogrel at the time of stenting compared with pretreatment 6 to 24 hours before percutaneous coronary intervention on the 30-day composite clinical end point in the large unselected patient cohort, which suggests the benefit of clopidogrel pretreatment in all incoming patients with suspected significant coronary artery disease scheduled for coronary angiography.
Comment in
-
Clopidogrel use with stenting.Expert Opin Pharmacother. 2007 Jun;8(9):1399-402. doi: 10.1517/14656566.8.9.1399. Expert Opin Pharmacother. 2007. PMID: 17563272 Clinical Trial.
Similar articles
-
Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001. Clin Ther. 2008. PMID: 19281914 Review.
-
Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome.Am Heart J. 2009 Feb;157(2):375-82. doi: 10.1016/j.ahj.2008.09.013. Epub 2008 Nov 1. Am Heart J. 2009. PMID: 19185648
-
Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting.Can J Cardiol. 2003 Aug;19(9):1041-6. Can J Cardiol. 2003. PMID: 12915931
-
Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents.Am Heart J. 2000 Sep;140(3):483-91. doi: 10.1067/mhj.2000.108825. Am Heart J. 2000. PMID: 10966552
-
[Optimal platelet inhibition after coronary stent implantation. Current status].Herz. 2008 Jun;33(4):244-53. doi: 10.1007/s00059-008-3138-9. Herz. 2008. PMID: 18581073 Review. German.
Cited by
-
Real-World Data on Potent P2Y12 Inhibition in Patients with Suspected Chronic Coronary Syndrome, Referred for Coronary Angiography.Cardiology. 2022;147(5-6):486-496. doi: 10.1159/000527459. Epub 2022 Oct 10. Cardiology. 2022. PMID: 36215960 Free PMC article.
-
Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry.J Am Heart Assoc. 2014 Apr 14;3(2):e000849. doi: 10.1161/JAHA.114.000849. J Am Heart Assoc. 2014. PMID: 24732921 Free PMC article.
-
Effect of pretreatment with a P2Y12 inhibitor in patients with non-ST-elevation acute coronary syndrome: a systematic review and network meta-analysis.Front Cardiovasc Med. 2023 Jul 19;10:1191777. doi: 10.3389/fcvm.2023.1191777. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37539086 Free PMC article. Review.
-
Short-term bleeding events observed with clopidogrel loading in acute ischemic stroke patients.J Stroke Cerebrovasc Dis. 2013 Oct;22(7):1184-9. doi: 10.1016/j.jstrokecerebrovasdis.2013.03.001. Epub 2013 Mar 29. J Stroke Cerebrovasc Dis. 2013. PMID: 23541421 Free PMC article.
-
Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus.Wien Med Wochenschr. 2010 Jan;160(1-2):30-8. doi: 10.1007/s10354-010-0747-8. Wien Med Wochenschr. 2010. PMID: 20229159 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical